Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Entrada Therapeutics Inc. The associated price target remains the same with $20.00.

Ram Selvaraju has given his Buy rating due to a combination of factors related to Entrada Therapeutics’ advancing clinical pipeline and upcoming catalysts. He highlights that the company is progressing multiple Duchenne muscular dystrophy programs (ENTR-601-44, -45, -50, -51) across the U.K., EU, and U.S., with several Phase 1/2 and Phase 1b studies underway or expected to start soon. Key near-term readouts, particularly from the ELEVATE-44-201 trial, are viewed as important potential drivers of value given their ability to demonstrate safety and efficacy at escalating dose levels. In addition, the partnered DM1 program VX-670 is advancing through its Phase 1/2 MAD study, with enrollment and dosing expected to complete in the first half of 2026, offering another meaningful data catalyst.

Selvaraju also emphasizes the strategic breadth of Entrada’s earlier-stage pipeline, especially in ophthalmology and metabolic disease, as a contributor to the positive outlook. The company has brought two ocular programs into lead optimization targeting inherited retinal disorders, using novel oligonucleotide-based approaches in indications with significant unmet medical need. The recent selection of ENTR-801 as a clinical candidate for Usher syndrome type 2A and plans to nominate an additional ocular candidate in 2026 further support long-term growth potential. Taken together, the imminent clinical data, expanding DMD and DM1 franchises, and emerging ophthalmology assets underpin his conviction in reiterating a Buy rating and a 12-month price target of $20.